Marea Therapeutics doses first patient in phase 2 acromegaly trial

October 5, 2026 8:00 AM

Marea Therapeutics, a subsidiary of Lisata Therapeutics (Nasdaq: LSTA), announced that the first patient has been dosed in a Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found